Login to Your Account

Dynavax's Early Stage Pipeline Advancing With $50M Vehicle

By Jennifer Boggs

Friday, April 21, 2006
With existing resources concentrated on late-stage development of two lead products, Dynavax Technologies Corp. entered a $50 million financing arrangement with Symphony Capital Partners LP to support work on its second-generation programs in cancer, hepatitis B and hepatitis C. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription